



## Corporate Press Release

2<sup>nd</sup> May 2012

### **Norgine and Pegasus Biosolutions enter partnership**

Norgine has announced that it has entered into a worldwide licensing agreement with Pegasus Biosolutions under which the two companies will collaborate to develop novel pharmaceutical products. Financial details of the agreement have not been disclosed but in addition to making an upfront payment, Norgine has also acquired a minority equity stake in Pegasus.

Commenting on the deal Peter Stein, Norgine's CEO said "We are delighted to enter into this agreement with Pegasus and look forward to working with such a creative research team."

"We are excited to be working with Norgine and we look forward to integrating the benefits of our mutual collaboration to better develop innovative products." added Urbi Ghosh, PhD, MBA, and President/CEO of Pegasus Biosolutions.

**Ends**

### **About Norgine**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €250 million and the company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL<sup>®</sup> for the treatment of constipation and faecal impaction, MOVIPREP<sup>®</sup> a bowel cleansing preparation, KLEAN-PREP<sup>®</sup> for large bowel preparation prior to colonoscopy or surgery, XIFAXAN<sup>®</sup> for the treatment of traveller's diarrhoea and ORAMORPH<sup>®</sup> for the treatment of moderate to severe pain associated with cancer.

S2012May01.01

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

For more information: [www.norgine.com](http://www.norgine.com)

**Norgine Contact:**

Julie Hornby-Winfield

Global Corporate Communications Manager

Tel: +44 1895 826600 or email [jhornbywinfield@norgine.com](mailto:jhornbywinfield@norgine.com)

**About Pegasus Biosolutions**

Pegasus Biosolutions is a biomedical company conducting research in infectious disease and head and neck cancer. The company was founded in 2011 by a group of entrepreneurs, expert physicians in gastroenterology, and a team of expert research scientists.

The team of expert scientists, physicians, and researchers at Pegasus Biosolutions have a unique expertise in cancer cell biology, genetics, oncology, gastroenterology and biomolecular research.

Pegasus Biosolutions LLC envisions revolutionizing prevention and treatment of head and neck cancer. A second research division is involved with prevention of infectious disease

**Pegasus Biosolutions Contact:**

Hemant K Roy

Chief Medical Officer

Tel: (847)881-6362 or email [hemant.roy@gmail.com](mailto:hemant.roy@gmail.com)